REG - Polarean Imaging PLC - Total voting rights and block listing return

Polarean ImagingAnnouncement

28/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220728:nRSb9754Ta&default-theme=true

RNS Number : 9754T  Polarean Imaging PLC  28 July 2022

Polarean Imaging Plc

("Polarean" or the "Company")

 

Total voting rights and Block Listing Return

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company,
with a proprietary drug‑device combination product using hyperpolarised
xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary
medicine, announces that the total number of shares in issue and total voting
rights as at the date of this announcement is 213,047,509 ordinary shares of
£0.00037 each ("Ordinary Shares").

 

The total issued share capital of the Company consists of 213,047,509 Ordinary
Shares. This number may be used by Shareholders as the denominator for the
calculation by which they will determine if they are required to notify their
interest in, or change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

 Name of applicant:                                                                Polarean Imaging Plc
 Name of scheme:                                                                   Polarean Share Option Plan
 Number and class of securities originally admitted:                               8,000,000 ordinary shares of £0.00037 each
 Date of admission:                                                                29 July 2021
 Period of return:                        From:                                    28 January 2022  To:              27 July 2022
 Balance of unallotted securities under scheme(s) from previous return:            7,556,970
 Plus: The amount by which the block scheme(s) has been increased since the        0
 date of the last return (if any increase has been applied for):
 Less: Number of securities issued/allotted under scheme(s) during period (see     3,531,313
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:         4,025,657
 Total number of securities in issue at the end of the period                      213,047,509

 

 Name of contact:              Richard Hullihen, Chief Executive Officer
 Telephone number of contact:  +44 (0)20 7933 8780 or polarean@walbrookpr.com

 

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Richard Hullihen, Chief Executive Officer                Via Walbrook PR
 Kenneth West, Chairman

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare
 Investment Banking)
 Nick Adams / Fred Walsh / Nick Harland (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy /Phillip Marriage         Mob: +44 (0)7879 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue-generating, investigational drug-device combination
companies operating in the high-resolution medical imaging research space.

 

The Group develops equipment that enables existing MRI systems to achieve an
improved level of pulmonary function imaging and specialises in the use of
hyperpolarised Xenon gas ((129)Xe) as an imaging agent to visualise
ventilation. (129)Xe gas is currently being studied for visualisation of gas
exchange regionally in the smallest airways of the lungs, across the alveolar
tissue membrane, and into the pulmonary bloodstream.

 

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA
for hyperpolarised (129)Xe used to evaluate pulmonary function and to
visualise the lung using MRI. The Group received a complete response letter on
5 October 2021. On 30 March 2022, the Company filed the resubmission of its
NDA with the US FDA and has received a PDUFA date of Sept 30, 2022.

 

The Group operates in an area of significant unmet medical need and the
Group's technology provides a novel investigational diagnostic approach,
offering a non-invasive and radiation-free functional imaging platform.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRFLFVEDLIDFIF